Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
about
Bivalirudin Anticoagulant Therapy With or Without Platelet Glycoprotein IIb/IIIa Inhibitors During Transcatheter Coronary Interventional Procedures: A Meta-AnalysisPercutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudinTirofiban for myocardial infarction.Actual Role of Platelet Glycoprotein IIb/IIIa Receptor Inhibitors as Adjunctive Pharmacological Therapy to Primary Angioplasty in Acute Myocardial Infarction: In the Light of Recent Randomized Trials and Observational Studies with Bivalirudin.Bivalirudin for primary percutaneous coronary intervention in acute myocardial infarction: the HORIZONS-AMI trial.Bivalirudin plus loading dose of cilostazol-based triple-antiplatelet in treatment of non-ST-elevation myocardial infarction following percutaneous coronary interventionSuccessful use of bivalirudin in place of heparin infusion for pulmonary vein isolation using a cryoballoon catheter in a patient with heparin allergy.Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary interventionAssociations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial.Percutaneous treatment in acute coronary syndromes.Restoration of microcirculatory patency after myocardial infarction: results of current coronary interventional strategies and techniques.Nucleic acid scavengers inhibit thrombosis without increasing bleeding.Bivalirudin decreases NO bioavailability by vascular immobilization of myeloperoxidase.Preoperative risk factors in 10 418 patients with prior myocardial infarction and 5241 patients with prior unstable angina undergoing elective coronary artery bypass graft surgery.Trends in use of anti-thrombotic agents and outcomes in patients with non-ST-segment elevation myocardial infarction (NSTEMI) managed with an invasive strategy.Heparin Versus Bivalirudin in Acute Myocardial Infarction: Unfractionated Heparin Monotherapy Elevated to Primary Treatment in Contemporary Percutaneous Coronary Intervention.Target populations and relevant therapeutic end points to further improve outcomes in NSTEACS patients.Automated surveillance to detect postprocedure safety signals of approved cardiovascular devices.Clinical applications of bivalirudin in the cardiac catheterization laboratory.Enoxaparin: a pharmacologic and clinical review.Glycoprotein IIb-IIIa inhibitors.Acute coronary syndromes: considerations for improved acceptance and implementation of management guidelines.Bleeding complications in patients with acute coronary syndromes: are they important and how can we prevent them?Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial.Bivalirudin in percutaneous coronary intervention, is it the anticoagulant of choice?Development of bioanalytical assays for variegin, a peptide-based bivalent direct thrombin inhibitor.Developing drugs for use before, during and soon after percutaneous coronary intervention.Risk stratification in acute coronary syndromes.The safety and effectiveness of bivalirudin in female patients with acute myocardial infarction undergoing primary angioplasty: A subgroup analysis of the BRIGHT trial.Low On-Treatment Platelet Reactivity Predicts Long-Term Risk of Bleeding After Elective PCI.Impact of anticoagulation regimen prior to revascularization in patients with non-ST-segment elevation acute coronary syndromes: The ACUITY trial.Intracoronary compared to intravenous abciximab in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention reduces mortality, target vessel revascularization and reinfarction after 1 year.Safety of bivalirudin in percutaneous coronary intervention following thrombolytic therapy.Bivalirudin use and one-month outcome in the context of contemporary antiplatelet treatment: insights from the Greek Antiplatelet Registry.Characterization of patients with bleeding complications who are at increased risk of death after percutaneous coronary intervention.Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trial.Antiplatelet Therapy for Non-ST-Segment Elevation Myocardial Infarction in Complex "Real" Clinical Scenarios: A Consensus Document of the "Campania NSTEMI Study Group".Novel Approaches for Preventing or Limiting Events (NAPLES III) Trial: randomised comparison of bivalirudin versus unfractionated heparin in patients at high risk of bleeding undergoing elective coronary stenting throught the femoral approach. ratioANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndrome
P2860
Q26798653-391FBF90-C79E-4AAB-A772-7FBD51A023A1Q33381356-8AE2A8C4-56A2-4EBC-A886-EC066AFE86A8Q33388527-74FE02D5-DD8C-480D-932C-C422BA27BB04Q33391341-8D114F9A-ECAA-455F-9677-E4DF05D88AC7Q33400450-4B861A8B-2BBD-440E-BC19-9CE64F78A188Q33426570-47829839-ED3E-4553-9A7C-4EC309EDEFF1Q33441751-60E4E91A-6AD9-4026-8421-E686BEBB5C1FQ33701953-BF582456-C447-4089-B464-7852601F712BQ34974622-701986AF-015E-4E4F-93AD-EDDD3F75BE9BQ35510430-D1ED4AA6-4839-4C10-BEAB-80598B94246AQ36011906-F9EF5856-F7F6-4ED9-8CD0-1E376D93ADF0Q36167707-A1D52281-D7D6-401E-879B-32120CA24B69Q36953866-FA5CCACD-DB8D-4716-ACA7-6D389DF297DAQ37095483-CA7DFD34-5B5A-455C-AC67-D06087A31393Q37188501-D9AD734C-ED0F-4A43-B64F-79136862ADE4Q37212502-CBE5A518-E2BE-44EB-8058-AE7565042B54Q37445883-BCC9574A-7E5C-40C8-879A-2BC3AD24ECC9Q37458616-E94746FA-C801-4A48-B7EF-121D2CBB1F4AQ37811622-557D0645-822D-4BA8-86D1-5C43C74BC379Q37862264-08A9C2CC-14D7-45B5-85AB-F663138D9DAFQ37942701-DFBA8587-8861-4F99-8232-9E016EBAC864Q37998114-41B7A943-9B33-4945-8A6C-A08EA2179206Q38012078-FE9C7188-0C01-4CF2-A00E-6B65F6E82ECDQ38375838-6DD96858-6E57-4BAD-ADD9-43C6431EEC12Q38423493-639A825E-DEA2-40FC-B248-C438C2F51418Q38685685-3B6C907A-D094-4C6E-AD12-5658EFC15689Q38708145-5461F6DC-8565-4BA6-AFC7-92617BA67293Q39680299-B65189E5-EDE4-4976-A8EC-0F3F3E2FA38BQ40980724-093323E9-31DB-45E4-95A7-5039AD491C11Q41069868-C4FE6F25-52F8-4D49-981A-F218CAA69E2CQ41430853-03CB90CA-931A-48E9-9609-9C330895858EQ43562848-27B6276B-CE54-4D5D-8F84-9D4102A0B426Q43570454-79CF6F18-4B26-4C78-A7C6-7909CCB7FF32Q44013094-4FFC190B-C8F0-4272-B10A-1E7F97BF1D1EQ44068850-3F1119CF-A5F3-45C8-8538-2B7E93B8F0BCQ44681767-117B7028-7FF7-475A-B895-BC4C3F867EF2Q50864337-CBB68351-E2AE-490F-8435-01C882931029Q53563183-900C643A-C398-4ED3-8A8D-FBEDAB242C89Q57764209-9401697B-7334-41A2-B52C-B93CCA70BD53
P2860
Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Antithrombotic strategies in p ...... results from the ACUITY trial.
@en
type
label
Antithrombotic strategies in p ...... results from the ACUITY trial.
@en
prefLabel
Antithrombotic strategies in p ...... results from the ACUITY trial.
@en
P2093
P50
P356
P1476
Antithrombotic strategies in p ...... results from the ACUITY trial.
@en
P2093
ACUITY Investigators
Antonio Colombo
Brent T McLaurin
David A Cox
Frederick Feit
Gregg W Stone
Harvey D White
James H Ware
Jeffrey W Moses
Martin Fahy
P304
P356
10.1001/JAMA.298.21.2497
P407
P577
2007-12-01T00:00:00Z